CANDEL THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.58 USD | +0.40% |
|
-5.60% | +415.65% |
| 05-30 | FDA Grants Candel Therapeutics' CAN-3110 Orphan Drug Designation to Treat Recurrent High-Grade Glioma | MT |
| 05-30 | Candel Therapeutics Gets FDA's Orphan-Drug Status for Glioma Treatment | DJ |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 226M 310M |
|---|---|---|---|---|---|
| Net income 2024 * | -41M -56.34M | Net income 2025 * | - | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-8.33
x | P/E ratio 2025 * |
-
| Employees | 42 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 66% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +0.40% | ||
| 1 week | -5.60% | ||
| Current month | -14.83% | ||
| 1 month | -18.67% | ||
| 3 months | +370.81% | ||
| 6 months | +650.50% | ||
| Current year | +415.65% |
1 week
6.76
7.97
1 month
6.7614.30
Current year
1.1614.30
1 year
0.6614.30
3 years
0.6614.78
5 years
0.6614.78
10 years
0.6614.78
| Managers | Title | Age | Since |
|---|---|---|---|
Paul-Peter Tak
CEO | Chief Executive Officer | 64 | 20-08-31 |
| Founder | 66 | 01-12-31 | |
Charles Schoch
DFI | Director of Finance/CFO | 39 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Joseph Papa
BRD | Director/Board Member | 68 | 22-08-07 |
Edward Benz
BRD | Director/Board Member | 78 | 17-08-31 |
Paul Manning
CHM | Chairman | 68 | 18-10-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-12 | 7.58 | +0.40% | 344,769 |
| 24-06-11 | 7.55 | +7.40% | 559,772 |
| 24-06-10 | 7.03 | -1.68% | 487,407 |
| 24-06-07 | 7.15 | +0.42% | 811,812 |
| 24-06-06 | 7.12 | -11.33% | 827,852 |
Delayed Quote Nasdaq, June 12, 2024 at 04:00 pm
More quotes
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The Company has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.
Calendar
2024-09-03
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
7.58
USD
Average target price
11
USD
Spread / Average Target
+45.12%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +415.65% | 226M | |
| +48.54% | 56.61B | |
| +37.01% | 39.25B | |
| -6.02% | 39.62B | |
| -6.90% | 28.28B | |
| +12.97% | 26.44B | |
| -16.91% | 20.12B | |
| +31.71% | 12.48B | |
| +28.18% | 12.51B | |
| +0.38% | 12.2B |
- Stock Market
- Equities
- CADL Stock
